BIOMÉRIEUX ● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The company has solid fundamentals for a short-term investment strategy.
Strengths
● Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 110.9 support.
● The company is in a robust financial situation considering its net cash and margin position.
● The group usually releases upbeat results with huge surprise rates.
● Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
● Over the past year, analysts have regularly revised upwards their sales forecast for the company.
● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
● For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
● The tendency within the weekly time frame is positive above the technical support level at 102 EUR
Weaknesses
● With an enterprise value anticipated at 4.35 times the sales for the current fiscal year, the company turns out to be overvalued.
● With a 2020 P/E ratio at 36.09 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
● The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
